The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Glutamine/amino acid transporter (ASCT2) is a novel prognostic marker and predicts metastases in colorectal cancer patients
Author(s): 
Pages: 2557-2559
Year: Issue:  10
Journal: Chinese Journal of Experimental Surgery

Keyword:  Colorectal cancerGlutamine/amino acid transporterGlutamine metabolism;
Abstract: Objective Glutamine/amino acid transporte(ASCT2 ikey transporteof glutamine thahabeen implicated in tumogrowth and metastasis.However, itclinical significance and role in colorectal cance(CRC) ilargely unknown.MethodThe expression of ASCT2 wadetermined by immunohistochemistry in Crsamples.The correlation of ASCT2 expression with clinicopathologifeaturewaanalyzed.Kaplan-Meiemethod and log-rank teswere used to estimate survival rate.Cox proportional hazardmodel waused to calculate multivariate hazard ratiofothe study variables.ResultASCT2 waup-regulated in mosof Crsamples, with high expression in 58 caseand low expression in 46 cases.There were 34 (57.1%) caseof tumosize largethan 3 cm, 42 (75.0%) cas1of lateTNM stages, 38 (64.3%) caseof lymph node metastasis, and 8 (28.6%) caseof livemetastasiin ASCT2 high expression group.Iwastatistically significanwhen compared to ASCT2 low expression group (P < 0.05).Patientwith high ASCT2 expression had pooreoverall survival than those with low ASCT2 expression [hazard ratio (HR) =2.32;95% confidence interval (CI) : 1.26-4.26;P <0.01].Furthermore,iwafound thaASCT2 expression waan independenprognostifactofoCRC.Conclusion These resultindicate thaASCT2 playcritical role in Crprogression, and may provide novel metabolism therapeutitargefoCRtreatment.
Related Articles
No related articles found